[{"id":"810b9ff0-cb3e-450e-9f8f-440c5a5e6576","acronym":"","url":"https://clinicaltrials.gov/study/NCT04626908","created_at":"2021-01-19T20:35:43.613Z","updated_at":"2025-02-25T14:59:30.158Z","phase":"Phase 1/2","brief_title":"Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT04626908","lead_sponsor":"He Huang","biomarkers":" CD19 • CD22","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GC022F"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/20/2020","start_date":" 11/20/2020","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2020-11-13"},{"id":"35cdc032-29a6-4e99-a7d5-d2b3f5f5832a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04412174","created_at":"2021-01-18T21:16:18.074Z","updated_at":"2025-02-25T14:59:08.827Z","phase":"Phase 1","brief_title":"A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL","source_id_and_acronym":"NCT04412174","lead_sponsor":"Hebei Yanda Ludaopei Hospital","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive • CD20 negative","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GC022F • S1904"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-06-02"},{"id":"af265f1e-7c8e-4e79-a08b-c9b1dc9436b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04129099","created_at":"2021-01-18T20:10:19.366Z","updated_at":"2025-02-25T15:08:51.386Z","phase":"Phase 1","brief_title":"A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL","source_id_and_acronym":"NCT04129099","lead_sponsor":"Hebei Yanda Ludaopei Hospital","biomarkers":" CD22","pipe":" | ","alterations":" CD19 expression • CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GC022F • S1904"],"overall_status":"Unknown status","enrollment":" Enrollment 18","initiation":"Initiation: 10/22/2019","start_date":" 10/22/2019","primary_txt":" Primary completion: 09/01/2020","primary_completion_date":" 09/01/2020","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2020-05-28"},{"id":"e019301d-43b0-4220-a310-76474b03ce88","acronym":"","url":"https://clinicaltrials.gov/study/NCT03825731","created_at":"2021-01-18T18:53:39.912Z","updated_at":"2025-02-25T15:08:17.722Z","phase":"Phase 1","brief_title":"A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL","source_id_and_acronym":"NCT03825731","lead_sponsor":"Hebei Yanda Ludaopei Hospital","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GC022F • S1904"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 01/17/2019","start_date":" 01/17/2019","primary_txt":" Primary completion: 09/16/2019","primary_completion_date":" 09/16/2019","study_txt":" Completion: 09/16/2019","study_completion_date":" 09/16/2019","last_update_posted":"2019-01-31"}]